QC
AVTX icon

Quadrature Capital’s Avalo Therapeutics AVTX Stock Holding History

Quadrature Capital’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.87M Buy
125,195
+72,151
+136% +$1.13M 0.02% 397
2025
Q4 		$963K Sell
53,044
-1,955
-4% -$33K 0.01% 528
2025
Q3 		$696K Buy
54,999
+44,023
+401% +$379K 0.01% 440
2025
Q2 		$54.8K Buy
+10,976
New +$51.3K ﹤0.01% 938

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Quadrature Capital's AVTX Position: Q1 2026 in Review

Quadrature Capital increased its Avalo Therapeutics (AVTX) stake by 136% in Q1 2026, buying an estimated $1.13M and bringing the position to 125,195 shares worth $1.87M. The position accounts for 0.02% of the portfolio, ranked #397.

Quadrature Capital first reported a position in AVTX in Q2 2025 and has held it in 4 quarters since. 97 funds tracked by Wall St. Rank hold AVTX as of Q1 2026.

  • Quadrature Capital held 125,195 shares of Avalo Therapeutics worth $1.87M as of Q1 2026.
  • Quadrature Capital bought 72,151 Avalo Therapeutics shares in Q1 2026, an estimated $1.13M.
  • Avalo Therapeutics made up 0.02% of Quadrature Capital's portfolio in Q1 2026, its #397 holding.
  • Quadrature Capital first reported a position in Avalo Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 97 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2026.

Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.